CD70 as a Radioligand Therapy Target
CD70, CD70 molecule, is a cell-surface protein. No tumor protein staining is recorded for it in Human Protein Atlas immunohistochemistry. Clinical status: Clinical-stage (up to phase 2, any modality), with 1 active clinical trial.
Is CD70 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ❌ Tumor expression: No tumor staining in HPA immunohistochemistry.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 2, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
CD70 expression in cancer
No Human Protein Atlas tumor immunohistochemistry data is available for CD70.
Is CD70 internalized?
Nuclens has not yet extracted internalization evidence for CD70. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
CD70 clinical trials
Clinical-stage (up to phase 2, any modality). 1 active trial reference CD70 (ClinicalTrials.gov, accessed 2026-09-14).
CD70 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CD70 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
CD70 gene essentiality (DepMap)
CRISPR knockout effect across 1256 cancer cell lines: 0.09 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
See how CD70 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.